Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ENGN

enGene Holdings Inc

May 03 • 02:03PM ET

15.23

Dollar change -0.09
Percentage change -0.59	%

Healthcare • Biotechnology • Canada • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.15	Insider Own	68.54%	Shs Outstand	23.20M	Perf Week	-1.74%
Market Cap	353.34M	Forward P/E	-	EPS next Y	-1.41	Insider Trans	-0.33%	Shs Float	7.30M	Perf Month	-7.13%
Income	-118.16M	PEG	-	EPS next Q	-0.26	Inst Own	21.36%	Short Float	1.00%	Perf Quarter	96.52%
Sales	0.00M	P/S	-	EPS this Y	99.15%	Inst Trans	1.29%	Short Ratio	1.19	Perf Half Y	-23.85%
Book/sh	2.69	P/B	5.66	EPS next Y	-13.44%	ROA	-99.86%	Short Interest	0.07M	Perf Year	46.44%
Cash/sh	3.69	P/C	4.12	EPS next 5Y	-	ROE	-119.64%	52W Range	6.69 - 47.17	Perf YTD	65.01%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-136.57%	52W High	-67.71%	Beta	-0.39
Dividend TTM	-	Quick Ratio	12.97	Sales past 5Y	0.00%	Gross Margin	-	52W Low	127.65%	ATR (14)	1.10
Dividend Ex-Date	Aug 03, 2015	Current Ratio	12.97	EPS Y/Y TTM	-271047.37%	Oper. Margin	0.00%	RSI (14)	46.16	Volatility	7.71% 7.23%
Employees	33	Debt/Eq	0.39	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	34.40
Option/Short	No / Yes	LT Debt/Eq	0.39	EPS Q/Q	-169.53%	Payout	-	Rel Volume	3.81	Prev Close	15.32
Sales Surprise	-	EPS Surprise	-10.84%	Sales Q/Q	-	Earnings	Mar 11 AMC	Avg Volume	60.98K	Price	15.23
SMA20	-1.86%	SMA50	-5.86%	SMA200	30.06%	Trades		Volume	165,998	Change	-0.59%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-24	Initiated	Wells Fargo	Overweight	$30
Apr-15-24	Initiated	Guggenheim	Buy	$34
Mar-28-24	Initiated	UBS	Buy	$37
Mar-08-24	Initiated	Morgan Stanley	Overweight	$40
Feb-20-24	Initiated	Leerink Partners	Outperform	$31

May-02-24 04:05PM	enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting (PR Newswire)
Apr-09-24 08:00AM	engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development (PR Newswire)
08:56AM	/C O R R E C T I O N -- enGene Inc./ (PR Newswire)
Mar-11-24 05:16PM	enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress (PR Newswire)
Mar-05-24 07:00AM	enGene To Present at the Leerink Partners Global Biopharma Conference (PR Newswire)
06:50AM	Loading…
Feb-14-24 06:50AM	enGene Announces Oversubscribed $200 Million Private Placement Financing (PR Newswire) +116.54%
06:45AM	enGene Announces Leadership Succession Plan (PR Newswire)
Jan-30-24 07:00AM	enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary (PR Newswire) -7.11%
Jan-29-24 07:00AM	enGene Reports Full Year 2023 Financial Results and Recent Operational Progress (PR Newswire)
Dec-22-23 05:00PM	enGene Announces Expanded $50 Million Debt Facility with Hercules Capital (PR Newswire)
Dec-19-23 07:00AM	enGene Appoints Lota S. Zoth, CPA, as Member of the Board of Directors (PR Newswire) +6.10%
Nov-29-23 07:00AM	enGene Appoints Ryan Daws as Chief Financial Officer (PR Newswire) -11.14%
Nov-13-23 09:55AM	Forbion co-leads 129 million Series A financing of VectorY, one of the largest private biotech financings in Europe in 2023 (GlobeNewswire) +5.36%
Nov-02-23 07:00AM	Lumira Ventures Portfolio Company enGene (Nasdaq:ENGN) Debuts as Publicly Traded Genetic Medicines Company (ACCESSWIRE) -5.00%
Nov-01-23 07:30AM	enGene (Nasdaq: ENGN) Launched as Publicly Traded Genetic Medicines Company (PR Newswire) -7.81%

enGene Holdings, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. It is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. The company was founded by Anthony T. Cheung on April 24, 2023 and is headquartered in Saint-Laurent, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FONDS DE SOLIDARITE DES TRAVAI	10% Owner	Apr 22 '24	Sale	15.00	47,854	717,810	3,036,153	Apr 22 05:22 PM
FONDS DE SOLIDARITE DES TRAVAI	10% Owner	Apr 19 '24	Sale	15.00	100	1,500	3,084,007	Apr 22 05:22 PM
FONDS DE SOLIDARITE DES TRAVAI	10% Owner	Apr 18 '24	Sale	15.01	4,575	68,671	3,084,107	Apr 22 05:22 PM
CHEUNG ANTHONY TZEYEW	Chief Technology Officer	Mar 18 '24	Option Exercise	0.89	52,940	47,117	102,873	Mar 20 04:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ENGN

enGene Holdings Inc

Upgrade your FINVIZ experience